Clinical trials of Fisetin in a person with autoimmune thyroiditis

Organisation: IntraClear Initiative
Supervisor: Ariel Feinerman
Medical advisor: Alexander Morozov

In recent years, clinical trials of drugs that affect extracellular and intracellular damage leading to ageing of the body have begun. You can find more info here [1].

For example, with age, senescent cells accumulate in our body. They cannot perform their functions normally, their abnormal metabolism is the cause of chronic inflammation, which plays an important role in ageing.

Relatively recently, senolitics, substances that selectively induce apoptosis (lead to programmed death) of senescent cells, have begun to be studied. Their studies have shown that when senescent cells are destroyed in old mice, they begin to look younger, and the function of their body improves.

In these studies, senolytic drugs have restored exercise capacity and capacity to form new blood and immune precursor cells in ageing mice to near youthful norms, while preventing age-related lung hypofunction, fatty infiltration into the liver, weakening or failure of the heart, osteoporosis, and hair loss. These treatments have also prevented or treated mouse models of diseases of ageing like osteoarthritis, fibrotic lung disease, nonalcoholic fatty liver disease (NAFLD), atherosclerosis, cancer and the side-effects of conventional chemotherapy, as well as neurodegenerative diseases of ageing like Parkinson’s and Alzheimer’s [2]!

Since senescent cells also arise in the immune system, being one of the causes of autoimmune diseases, there is a hypothesis that the destruction of senescent cells will help in the prevention and treatment of many autoimmune diseases.

It is important that the mechanisms of cell senescence and the effects of their destruction by senolitics are similar in mice and humans. For example, it has been shown that the combination of dasatinib (a relatively aggressive chemotherapeutics) and quercetin (flavonoid) works in humans as well as in mice when it comes to destruction of senescent cells [3].

Some drugs that have established senolytic effects are available for purchase just now. However, they are usually used in much lower dosages than is required for the senolytic effect. Such substances include the readily available and cheap bioactive flavonoid fisetin.

Mice experiments show that fisetin is about as effective against senescent cells as the dasatinib + quercetin combination. The advantage of fisetin, which is a plant substance, is its safety compared to many other drugs that have shown a senolytic effect [4].

There are currently three clinical trials in humans. They are conducted in Mayo Clinic (USA), where a special treatment protocol was developed. Mayo Protocol consists in taking 20 mg / kg of fisetin orally for two days in a row, after which a person takes the second course after a month or two months [5].

Clinical Trials at Mayo Clinic

Because of the availability and safety of fisetin, we decided to conduct our own clinical trials of this drug in a person with autoimmune thyroiditis. It is noteworthy that, unlike most tests, we focus not on chronic inflammation, but on immune function.

Patient information

Before taking fisetin, we will determine the biochemical parameters of the functions of various organs and systems, focusing on the chronic inflammation and immune function. After the course of taking fisetin, we will repeat the study. The subjective sensations of a person will also be recorded.

If the experiment shows success, it will lay the basis for a large-scale clinical trial and will open up prospects for the prevention and treatment of autoimmune diseases.

For these tests, we need your financial help. For measurements, $1,054 are needed, of which $110 were collected, and $944 are still needed.

You can help via PalPal arielfeinerman@gmail.com or form

Primary measures

Stay tuned for future trial information with the Future Collector!

Links

1. Steve Hill, Nicola Bagalà, The First Rejuvenation Therapy Reaches Human Trials.

2. Michael Rae, Senolytics – Solution or Self-Defeating for Senescent Cells?

3. Hickson LJ, Langhi Prata LGP, Bobart SA, Evans TK, Giorgadze N, Hashmi SK, Herrmann SM, Jensen MD, Jia Q, Jordan KL, Kellogg TA, Khosla S, Koerber DM, Lagnado AB, Lawson DK, LeBrasseur NK, Lerman LO, McDonald KM, McKenzie TJ, Passos JF, Pignolo RJ, Pirtskhalava T, Saadiq IM, Schaefer KK, Textor SC, Victorelli SG, Volkman TL, Xue A, Wentworth MA, Wissler Gerdes EO, Zhu Y, Tchkonia T, Kirkland JL. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019 Sep;47:446-456. doi: 1016/j.ebiom.2019.08.069. Epub 2019 Sep 18. PubMed PMID: 31542391.

4. Yousefzadeh MJ, Zhu Y, McGowan SJ, Angelini L, Fuhrmann-Stroissnigg H, Xu M, Ling YY, Melos KI, Pirtskhalava T, Inman CL, McGuckian C, Wade EA, Kato JI, Grassi D, Wentworth M, Burd CE, Arriaga EA, Ladiges WL, Tchkonia T, Kirkland JL, Robbins PD, Niedernhofer LJ. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018 Oct;36:18-28. doi: 1016/j.ebiom.2018.09.015. Epub 2018 Sep 29. PubMed PMID: 30279143; PubMed Central PMCID: PMC6197652.

5. Cari Green, Michael Greve, Fisetin Senolytic Therapy